Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1965 2
1966 1
1967 1
1972 2
1976 7
1977 4
1978 9
1979 12
1980 5
1981 10
1982 5
1983 10
1984 6
1985 15
1986 11
1987 17
1988 12
1989 14
1990 13
1991 12
1992 16
1993 18
1994 16
1995 28
1996 22
1997 19
1998 12
1999 13
2000 12
2001 9
2002 10
2003 8
2004 12
2005 5
2006 2
2007 7
2008 4
2009 6
2010 8
2011 5
2012 3
2013 1
2014 1
2017 1
2018 2
2019 2
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Baden LR, et al. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. N Engl J Med. 2021. PMID: 33378609 Free PMC article. Clinical Trial.
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. El Sahly HM, et al. N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22. N Engl J Med. 2021. PMID: 34551225 Free PMC article. Clinical Trial.
MALT Lymphomas.
Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. Cavalli F, et al. Among authors: isaacson pg. Hematology Am Soc Hematol Educ Program. 2001:241-58. doi: 10.1182/asheducation-2001.1.241. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722987 Review.
Gastrointestinal lymphoma.
Isaacson PG. Isaacson PG. Hum Pathol. 1994 Oct;25(10):1020-9. doi: 10.1016/0046-8177(94)90060-4. Hum Pathol. 1994. PMID: 7927306
Update on MALT lymphomas.
Isaacson PG. Isaacson PG. Best Pract Res Clin Haematol. 2005 Mar;18(1):57-68. doi: 10.1016/j.beha.2004.08.003. Best Pract Res Clin Haematol. 2005. PMID: 15694184 Review.
Splenic marginal zone lymphoma.
Dogan A, Isaacson PG. Dogan A, et al. Among authors: isaacson pg. Semin Diagn Pathol. 2003 May;20(2):121-7. doi: 10.1016/s0740-2570(03)00012-1. Semin Diagn Pathol. 2003. PMID: 12945935 Review.
Intestinal lymphoma and enteropathy.
Isaacson PG. Isaacson PG. J Pathol. 1995 Oct;177(2):111-3. doi: 10.1002/path.1711770202. J Pathol. 1995. PMID: 7490675 Review. No abstract available.
MALT lymphoma: from morphology to molecules.
Isaacson PG, Du MQ. Isaacson PG, et al. Nat Rev Cancer. 2004 Aug;4(8):644-53. doi: 10.1038/nrc1409. Nat Rev Cancer. 2004. PMID: 15286744 Review. No abstract available.
409 results